Lexaria Bioscience Warrant
LEXXW
LEXXW was delisted on the 13th of January, 2026.
4 hedge funds and large institutions have $802K invested in Lexaria Bioscience Warrant in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
20% less funds holding
Funds holding: 5 → 4 (-1)
33% less capital invested
Capital invested by funds: $1.2M → $802K (-$402K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$19.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
-$2.99K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $383K | +$19.2K | +17,069 | +4% |
|
|
BFM
2
Boothbay Fund Management
New York
| $261K | – | – | – |
|
|
EAM
3
Empery Asset Management
New York
| $118K | -$2.99K | -2,651 | -2% |
|
|
CH
4
CVI Holdings
Wilmington,
Delaware
| $40K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| – | -$1K | -784 | Closed |
|
LEXXW Hedge Fund Activity: Q1 2022 in Review
4 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience Warrant (LEXXW) for Q1 2022, worth a combined $802K — down 33% from $1.2M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of LEXXW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Sabby Management, adding an estimated $19.2K. The largest seller was Empery Asset Management, cutting an estimated $2.99K.
- 4 institutional investors held Lexaria Bioscience Warrant (LEXXW) as of Q1 2022, down from 5 in Q4 2021.
- Funds reported $802K of Lexaria Bioscience Warrant stock for Q1 2022, down 33% quarter-over-quarter.
- 0 funds opened new Lexaria Bioscience Warrant positions in Q1 2022 and 1 closed out, a net change of -1 holder.
- The largest Lexaria Bioscience Warrant buyer in Q1 2022 was Sabby Management, an estimated $19.2K added.
- The largest Lexaria Bioscience Warrant seller in Q1 2022 was Empery Asset Management, an estimated $2.99K sold.
Based on aggregated 13F filings for Q1 2022.